Thursday, 17 October 2019
Latest news
Main » Anthera Pharmaceuticals (NASDAQ:ANTH) Covered By Yet Another Research Firm

Anthera Pharmaceuticals (NASDAQ:ANTH) Covered By Yet Another Research Firm

23 February 2018

On 9/7/2017 John Craig Thompson, CEO, bought 10,400 with an average share price of $1.43 per share and the total transaction amounting to $14,872.00. With 979,000 shares average volume, it will take short sellers 2 days to cover their ANTH's short positions.

The stock is trading -61.06% away from its 52 week high of $6.24 and 102.5% far from the stock's low point over the past 52 weeks, which was $1.20. Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) has declined 60.96% since February 22, 2017 and is downtrending. It has underperformed by 4.72% the S&P500.

Shares of Anthera Pharmaceuticals closed the previous trading session at 2.05 up +0.36 21.29% with shares trading hands. (NASDAQ:ANTH) is a huge mover today! About 36.63 million shares traded or 3186.66% up from the average.

More news: (MSFT) EVP Christopher C. Capossela Sells 3500 Shares

Several analysts have released their opinion on Anthera Pharmaceuticals, Inc. We have $2.37 PT which if reached, will make NASDAQ:ANTH worth $2.43M more. Henson Christopher L also sold $2.01 million worth of BB&T Corporation (NYSE:BBT) shares.

Anthera Pharmaceutic (NASDAQ:ANTH) has an ABR of 2.33 which is the combined stock view of 3 analysts poll results. Therefore 22% are positive. The stock has "Hold" rating by Robert W. Baird on Friday, August 25. As per Tuesday, February 13, the company rating was maintained by Jefferies. The rating was maintained by Jefferies with "Hold" on Monday, June 26. On Wednesday, September 9 the stock rating was initiated by SunTrust with "Buy". Its down 0.16, from 0.63 in 2017Q2. The SI to Diversified Restaurant Holdings Inc's float is 0.13%. Earnings per share serves as an indicator of a company's profitability. (NASDAQ:FARM) for 213 shares. Orbimed Advsrs Ltd reported 0.03% of its portfolio in Infinity Pharmaceuticals, Inc. (NASDAQ:FARM) for 16,800 shares.

Gw Henssler & Associates Ltd increased Abbott Labs (NYSE:ABT) stake by 7,344 shares to 254,889 valued at $13.60 million in 2017Q3. Blackrock Incorporated stated it has 0% in Infinity Pharmaceuticals, Inc. Vnbtrust National Association, Virginia-based fund reported 11,869 shares. First Lp has invested 0% in Farmer Bros. Co. (NASDAQ:INFI) for 459,000 shares. Willingdon Wealth Mngmt holds 1,735 shares or 0.03% of its portfolio. (NASDAQ:INFI) or 118,435 shares. Parsons Cap Mngmt Inc Ri holds 0.04% of its portfolio in BB&T Corporation (NYSE:BBT) for 6,902 shares. With an institutional ownership near 33.6%, it carries an earnings per share ratio of -0.74. (NASDAQ:INFI) for 45,985 shares. The company has market cap of $32.06 million. The Company's clinical-stage programs include one Phase 3 ready program, A-002, and two Phase 2 clinical programs, A-623 and A-001.

More news: Curling - US add to Canadian misery with semi-final win

The company's Average Earnings Estimate for the Current Fiscal quarter is $-0.48, according to consensus of 3 analysts.'s article titled: "Anthera Pharmaceuticals to Participate in the BIO CEO & Investor Conference ..." and published on February 08, 2018 is yet another important article.

Analysts are expecting average earnings estimates of $-0.66 for the current quarter based on the opinion of 4 analysts, relating to high earnings per share estimates of $-0.49 and low estimates of $-0.87, however Anthera Pharmaceutic (NASDAQ:ANTH) reported $-3.2 earnings per share for the same quarter a year ago. Therefore 67% are positive.

According to Zacks, "Anthera Pharmaceuticals, a biopharmaceutical company focused on developing and commercializing products to treat serious illnesses, including cardiovascular and autoimmune diseases". The firm has "Buy" rating by H.C. Wainwright given on Friday, July 8. The firm has "Buy" rating given on Thursday, September 17 by Citigroup.

More news: Alex Trebek: Running for office 'a possibility'

Director, Truex Paul F, purchased 5,000 common shares of Anthera Pharmaceuticals, Inc. Deutsche Bank maintained BB&T Corporation (NYSE:BBT) on Tuesday, April 5 with "Hold" rating. (NASDAQ:ANTH) has "Hold" rating given on Sunday, August 6 by Jefferies. The firm has "Buy" rating given on Thursday, December 29 by H.C. Wainwright. On Wednesday, November 15 the stock rating was maintained by Jefferies with "Hold". They issued a "buy" rating and a $10.00 price objective on the stock. The firm has "Neutral" rating by Citigroup given on Thursday, December 29. On Friday, February 19 the stock rating was reinitiated by Jefferies with "Buy".